An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma

Terminated

• Conditions: Lymphoma, Follicular

• Registration Number: NCT01609036
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-05-29
• Study First Submitted QC: 2012-05-29
• Study First Posted: 2012-05-31
• Study Start: 2012-10
• Primary Completion: 2012-11
• Study Completion: 2012-11
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-01
• Last Update Posted: 2016-11-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• Adult patients, >/=18 years
• Patients with previously untreated follicular lymphoma (stage III-IV) according to the approved summary of product characteristics (SPC)

Read More

Exclusion Criteria

• Contraindications to MabThera/Rituxan therapy according to the approved SPC

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety: Incidence of adverse events	3 years

Secondary Outcome Measures

Name	Time	Method
Overall survival	3 years
Event-free survival	3 years
Progression-free survival	3 years